Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) and Zura Bio (NASDAQ:ZURA – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.
Risk & Volatility
Dianthus Therapeutics has a beta of 1.22, meaning that its stock price is 22% more volatile than the S&P 500. Comparatively, Zura Bio has a beta of -0.02, meaning that its stock price is 102% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Dianthus Therapeutics and Zura Bio, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Dianthus Therapeutics | 1 | 0 | 12 | 1 | 2.93 |
| Zura Bio | 1 | 0 | 5 | 1 | 2.86 |
Insider and Institutional Ownership
47.5% of Dianthus Therapeutics shares are owned by institutional investors. Comparatively, 61.1% of Zura Bio shares are owned by institutional investors. 3.0% of Dianthus Therapeutics shares are owned by insiders. Comparatively, 12.4% of Zura Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Dianthus Therapeutics and Zura Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Dianthus Therapeutics | -10,096.95% | -22.53% | -21.55% |
| Zura Bio | N/A | -56.13% | -50.15% |
Earnings & Valuation
This table compares Dianthus Therapeutics and Zura Bio”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Dianthus Therapeutics | $2.04 million | 2,968.53 | -$162.34 million | ($4.15) | -26.69 |
| Zura Bio | N/A | N/A | -$99.35 million | ($1.13) | -5.46 |
Zura Bio has lower revenue, but higher earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks.
Summary
Zura Bio beats Dianthus Therapeutics on 7 of the 13 factors compared between the two stocks.
About Dianthus Therapeutics
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
About Zura Bio
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.
Receive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
